Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

DNDi R&D Projects

DNDi Portfolio June 2015

 
  ScreenHit to
lead
Lead Opt.Pre-clinicalPhase IPhase IIa/PoCPhase IIIb/IIIRegistrationAccess
 
 

SCYX1330682

SCYX1608210

 

SCYX‑7158

 

Fexinidazole

 

NECT
Nifurtimox-Elfornithine Combination Therapy

   
Screening
 

Nitroimidazoles

     

Oxaleish

 
   

Amino pyrazoles

Leish H2L

     

Fexi sulfone

 
 
 

CpG-D35
(CL)

 

Fexi/MF Combo

   
 
 
   

Anfoleish
(CL)

New CL Combos

 

New Treatments for HIV/VL

 

PKDL
Asia/
Africa

 

New VL treatments
Latin America

SSG&PM
Africa

New VL treatments
Asia

   

Chagas 2HL

   
 

Biomarkers

 

New Benz Regimens/
Combos

Fexinidazole

   

Benznidazole
Paediatric
Dosage Form

   
 
 

Macro Filaricide 2

Emodepside

 
 
       

Two '4-in-1' LPV/r
based FDC granules

 

LPV/r pellets with
dual NRTI FDC

 
     

Superbooster
HIV/TB

 

ASAQ FDC
Artesunate‑Amodiaquine
Fixed‑Dose Combination

ASMQ FDC
Artesunate‑Mefloquine
Fixed‑Dose Combination

 
           

Fosravuconazole

   

New Chemical Entity (NCE)
Fexinidazole (for HAT, VL, and Chagas disease) = 1 NCE

 

  • Browse DNDi 2013 Portfolio Map: [Flippable]
  • Download PDF: EnglishSpanishPortugueseJapanese


Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License